CRISPR Therapeutics Stock Plunges 6.98% as $250M Volume Slumps to 424th in Market Activity

On October 3, 2025, CRISPR Therapeutics (CRSP) closed with a 6.98% decline, trading at a volume of $0.25 billion, ranking 424th in market activity for the day. The selloff followed a series of strategic updates and operational developments within the gene-editing sector, though no direct catalysts from the company were disclosed in the referenced materials.

Analysts noted muted investor sentiment amid broader sector volatility, with CRISPR's performance reflecting cautious positioning ahead of potential data releases from ongoing clinical trials. The stock's decline aligned with broader trends in biotech equities, where risk-off behavior dominated despite recent advancements in therapeutic pipelines.

To run this back-test accurately I’ll need to clarify a couple of details: 1. Market universe • Are we talking about U.S.-listed equities only (e.g., all common stocks on NYSE + NASDAQ), or another market? 2. Execution prices • Do you want to open positions at the day’s close and exit at the next day’s close (close-to-close), or open at the next day’s open and exit at that day’s close (open-to-close), etc.? 3. Weighting • Should the 500 names be equal-weighted each day, or weighted by volume, dollar-neutral, etc.? 4. Benchmark / comparison (optional) • Would you like the strategy’s returns compared against a benchmark index (e.g., S&P 500 ETF SPY)? Once I have these points, I can build the data-retrieval plan and run the back-test.